hotspot -WSS

hotspot

author：fashion 2025-10-02 18:48:56 - browse：99

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration said Monday that it has deep reservations about NurOwn, an investigational ALS treatment from BrainStorm Cell Therapeutics, citing a lack of evidence that the medicine works and the company’s failure to demonstrate that it can properly manufacture the product.

In documents disclosed ahead of a Wednesday public hearing on NurOwn’s application for approval, the FDA detailed its problems with a clinical trial that missed its primary objective and noted that BrainStorm submitted “grossly deficient” information on how the medicine is made, voicing “major concerns that the available data do not meet the statutory standard of substantial evidence of effectiveness to support” approval.

BrainStorm filed for approval over the FDA’s protest, insisting that NurOwn has demonstrated benefits for a subset of ALS patients with milder disease. That conclusion, based on an after-the-fact analysis of the company’s failed pivotal trial, has proved polarizing among patients and physicians, with some arguing that the FDA should exercise flexibility in light of the irrevocably fatal nature of ALS and others demanding BrainStorm conduct another clinical trial to demonstrate its benefits.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Addiction experts warn against a second 'war on drugs'

WSS

Burning questions about Delta and the next phase of the Covid pandemic

Mike Pence ‘not interested in trading insults’ with Trump as he tries to win New Hampshire

Helping hospitals and community health centers plan for resilience

Woman found dead after suspected bear encounter near Yellowstone, wildlife officials say

Anxious about a speech? A startup wants you to pop a minty cardiac drug

Glen Campbell's doctor discusses his public struggle with Alzheimer's

focus

hotspot

knowledge

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Addiction experts warn against a second 'war on drugs'

How one medical school became remarkably diverse

HIV vaccine remains elusive. Immunologists keep trying new ideas

United colonoscopy coverage change 'may cost lives,' doctors say

How a key Senate committee is planning to regulate PBMs

State Dept. review finds Biden bears some blame for Afghanistan failures

How a key Senate committee is planning to regulate PBMs

Jerome Adams on the need for new antivirals for Covid

Thousands protest mob assault of women who were paraded naked in remote Indian border state

Wikipedia

Sophia Smith scores twice for US in in 3

Statins reduce cardiovascular risk in people living with HIV

FDA approves first blood sugar monitor without finger pricks

Big Tobacco's 'harm reduction': Is it for real, or a sham?

Thousands protest mob assault of women who were paraded naked in remote Indian border state

Statins reduce cardiovascular risk in people living with HIV

hotspot

focus

hotspot

explore